ReviewNature reviews. Cancer2010
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.
Review in Nature reviews. Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 205 citations in OpenAlex.
- Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.Human vaccines & immunotherapeutics · 2026Article
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- White paper on best practices for translational research in neuroendocrine neoplasms.Journal of neuroendocrinology · 2025Article
- Computationally Designed Nanobinders as Affinity Ligands in Diagnostic and Therapeutic Applications.Journal of the American Chemical Society · 2025Article
- PTMFusionNet: A Deep Learning Approach for Predicting Disease Related Post-translational Modification and Classifying Disease Subtypes.Molecular & cellular proteomics : MCP · 2025Article
- Single-cell multi-omics in the study of digestive system cancers.Computational and structural biotechnology journal · 2024Review
- Unveiling the power of proteomics in advancing tropical animal health and production.Tropical animal health and production · 2024Article
- Spatial Biology of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2024Review
- Improving de novo protein binder design with deep learning.Nature communications · 2023Article
- Article
- The geometry of clinical labs and wellness states from deeply phenotyped humans.Nature communications · 2021Article
- High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale.iScience · 2021Article
- Towards Building a Quantitative Proteomics Toolbox in Precision Medicine: A Mini-Review.Frontiers in physiology · 2021Review
- Editorial: Application of Systems Biology in Molecular Characterization and Diagnosis of Cancer.Frontiers in molecular biosciences · 2021Article
- Programmable Bivalent Peptide-DNA Locks for pH-Based Control of Antibody Activity.ACS central science · 2020Article
- Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour.EBioMedicine · 2020Article
- Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms.Frontiers in microbiology · 2020Review
- Heterogeneous Strategies to Eliminate Intracellular Bacterial Pathogens.Frontiers in microbiology · 2020Review
- Applying Machine Learning of Erythrocytes Dynamic Antigens Store in Medicine.Frontiers in molecular biosciences · 2019Article
- Integrated analysis of transcription factors and targets co-expression profiles reveals reduced correlation between transcription factors and target genes in cancer.Functional & integrative genomics · 2019Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effective implementation of personalized cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity reagents in clinical diagnostic and predictive assays suggests that the rapid translation of such approaches is an achievable goal. Furthermore, in combination with, or as alternatives to, genomic and transcriptomic methods for patient stratification, antibody-based proteomics approaches offer the promise of additional insight into cancer disease states. In this Review, we discuss the current status of antibody-based proteomics and its contribution to the development of new assays that are crucial for the realization of individualized cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.